Dyax Announces Final Patient Treated in Pivotal Phase III Clinical Trial (EDEMA3) for DX-88 in Hereditary Angioedema
Dyax Corp. announced that it has completed the double-blind portion of its pivotal Phase III clinical trial, known as EDEMA3, for its lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). In addition, the U.S. Food and Drug Administration has also broadened the Fast Track designation for DX-88 for the treatment of all types of acute HAE attacks, a rare and life-threatening inflammatory condition for which there is no approved therapy in the United States.
First Patient Treated in Phase III Ovarian Cancer Trial
Marshall Edwards, Inc. announced that the first patient had commenced treatment in the Phase III "OVATURE" clinical trial at The Royal Women's Hospital in Melbourne, Australia.
Royal Women's is one of 60 hospitals that will be participating in this multi-center multi-national ovarian cancer study to confirm the effectiveness of phenoxodiol in resensitizing patients to chemotherapy.
SOMAXON REPORTS RESULTS FROM THIRD PHASE III STUDY OF SILENOR
Somaxon Pharmaceuticals has announced positive results from its Phase III clinical trial evaluating Silenor (doxepin HCl) in elderly patients with primary sleep maintenance insomnia. The drug demonstrated a statistically significant improvement compared with placebo in the primary endpoint of this trial, subjective total sleep time as measured at week one. Statistical significance was maintained for all time points measured throughout the four-week treatment period.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment